Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Generic Name
- Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于：1.恶性肿瘤、白血病化、放疗引起的白血病减少及其并发的感染；
2.造血干/祖细胞移植后髓系造血功能受抑及延迟植活与移植排斥；
3.与rhG-CSF等造血生长因子联合或单独应用于外周血造血干/祖细胞移植前的干/祖细胞动员；
4.再生障碍性贫血等骨髓衰竭性疾患及各种严重感染并发的中性粒细胞减少；
5.也可用于艾滋病本身、或因药物治疗所致的中性粒细胞减少。
- Associated Conditions
- -
- Associated Therapies
- -
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-07-26
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- UbiVac
- Target Recruit Count
- 12
- Registration Number
- NCT01909752
- Locations
- 🇺🇸
LSU Stanley S. Scott Cancer Center, New Orleans, Louisiana, United States
🇺🇸Providence Cancer Center, Portland, Oregon, United States
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Epitopoietic Research Corporation
- Target Recruit Count
- 84
- Registration Number
- NCT01903330
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸University of California, Irvine, Orange, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Therapy for Children With Advanced Stage Neuroblastoma
- Conditions
- Interventions
- Drug: cyclophosphamideDrug: topotecanBiological: hu14.18K322AProcedure: peripheral blood stem cell harvestProcedure: surgical resectionDrug: cisplatinDrug: etoposideDrug: doxorubicinDrug: vincristineDrug: busulfanDrug: melphalanBiological: peripheral blood stem cell transplantationBiological: natural killer cell infusionRadiation: radiation therapyBiological: GM-CSFBiological: G-CSFDrug: mesnaDrug: levetiracetamBiological: interleukin-2Drug: IsotretinoinDevice: CliniMACS
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 153
- Registration Number
- NCT01857934
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Sellas Life Sciences Group
- Target Recruit Count
- 22
- Registration Number
- NCT01827137
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
- First Posted Date
- 2012-04-04
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- George E. Peoples
- Target Recruit Count
- 275
- Registration Number
- NCT01570036
- Locations
- 🇺🇸
University of Miami, Plantation, Florida, United States
🇺🇸Memorial Hospital of South Bend, South Bend, Indiana, United States
🇺🇸Texas Oncology (Cancer Care Centers of South Texas), San Antonio, Texas, United States
Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2014-04-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT01542684
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Ipilimumab and GMCSF Immunotherapy for Prostate Cancer
- First Posted Date
- 2012-02-10
- Last Posted Date
- 2015-10-05
- Lead Sponsor
- Lawrence Fong
- Registration Number
- NCT01530984
- Locations
- 🇺🇸
University of California, San Francisco, California, United States
GM-CSF for Immunomodulation Following Trauma (GIFT) Study
- First Posted Date
- 2011-12-20
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Mark Hall
- Target Recruit Count
- 108
- Registration Number
- NCT01495637
- Locations
- 🇺🇸
Cincinnati Children's Medical Center, Cincinnati, Ohio, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
The Effects of Immunostimulation With GM-CSF or IFN-y on Immunoparalysis Following Human Endotoxemia
- Conditions
- Interventions
- First Posted Date
- 2011-06-16
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT01374711
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-03-24
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 1297
- Registration Number
- NCT01322490
- Locations
- 🇺🇸
Alaska Clinical Research Center, Llc, Anchorage, Alaska, United States
🇺🇸Scottsdale Healthcare, Scottsdale, Arizona, United States
🇺🇸Alta Bates Summit Medical Center, Berkeley, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.